Epiphora in lung cancer patients receiving docetaxel: a case series

Yamagishi, Tomoko; Ochi, Nobuaki; Yamane, Hiromichi; Hasebe, Shinji; Takigawa, Nagio

doi:10.1186/1756-0500-7-322

Cited by 10 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding was similar to the past reports. 17,18,20 In the present study, two patients had a stye (Table 4). The symptoms of both patients improved with the use of oral cefcapene.…”

Section: Discussionmentioning

confidence: 49%

“…In past reports, the cumulative dose tended to be higher than in the present study. 15,17,20 For that reason, watering eyes tends to be more frequent. 17 Cases with irreversible symptoms or requiring treatment such as silicone intubation were also reported.…”

Section: Discussionmentioning

confidence: 99%

“…17 Cases with irreversible symptoms or requiring treatment such as silicone intubation were also reported. 15,17,20 From the above, it is considered that a higher cumulative dose is a risk factor of eye disorders.…”

Section: Discussionmentioning

confidence: 99%

“…[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Watering eyes and lacrimal duct obstruction have been frequently reported. [10][11][12][13][14][15][16][17][18][19][20] Intravenously administered DTX is distributed to the tear fluid from the plasma. 11 Nasolacrimal duct obstruction secondary to treatment with DTX may be, in part, due to stromal fibrosis in the mucosal lining of the lacrimal drainage apparatus.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Noguchi

Kawashima²,

Maruyama³

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of ≥300 mg/m2 (odds ratio: 15.50, 95% confidence interval: 1.37–175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13–153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.

show abstract

“…This finding was similar to the past reports. 17,18,20 In the present study, two patients had a stye (Table 4). The symptoms of both patients improved with the use of oral cefcapene.…”

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Noguchi

Kawashima²,

Maruyama³

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Ductal stenosis is believed to contribute to epiphora and is likely caused by chronic inflammation of the canaliculi caused by direct contact with docetaxel, which is secreted in the tear film 11. Probing and irrigation has been described to resolve the epiphora,12 and cases 2–3 demonstrate consistent findings. In case 1, halving the dose of docetaxel resulted in complete resolution.…”

Section: Discussionmentioning

confidence: 99%

Periorbital dermatitis in patients receiving docetaxel in combination chemotherapy

Tabata¹,

Kwong

2019

BMJ Case Rep

View full text Add to dashboard Cite

Recognition of new cutaneous side effects of combination chemotherapy can help prevent unnecessary cessation or reduction of cancer therapy. Periorbital rash has not been found with docetaxel alone, but here, we report it as a result of combination chemotherapy. A series of three patients who received docetaxel in combination with other chemotherapies developed clinically near-identical, distinctive periorbital rashes. Rashes resolved by resolving underlying docetaxel-induced epiphora in conjunction with ophthalmological consultation, topical skin-directed care, and in some cases, chemotherapy dose reduction. It is important for dermatologists and oncologists to recognise the increased severity of cutaneous reactions when docetaxel is used in combination chemotherapy.

show abstract

Risk of Ocular Adverse Events With Taxane-Based Chemotherapy

et al. 2022

View full text Add to dashboard Cite

IMPORTANCE Taxane-based chemotherapy agents, such as docetaxel and paclitaxel, are used for treating a wide range of cancers. Although much has been published on adverse events related to taxanes, data on ocular outcomes with these very important drugs are scant. OBJECTIVE To quantify the risk of 3 mutually exclusive ocular adverse events of epiphora, cystoid macular edema (CME), and optic neuropathy with taxane-based chemotherapy agents by undertaking a large pharmacoepidemiologic study. DESIGN, SETTING, AND PARTICIPANTSThis retrospective cohort study design used a private health-claims database from the US that captures health information of more than 150 million enrollees. The study team created a cohort of new users of women with cancer who were taking taxane-based chemotherapy (docetaxel or paclitaxel) and new users of tamoxifen as controls. Study members were observed to the first incidence of each of the 3 mutually exclusive outcomes. An analysis of taxane-only users was also undertaken.EXPOSURE Tamoxifen (unexposed) and taxanes (ie, paclitaxel and docetaxel) as the exposed.MAIN OUTCOMES AND MEASURES First diagnosis of (1) epiphora, (2) cystoid macular edema (CME), or (3) optic neuropathy ascertained using

show abstract

Epiphora in lung cancer patients receiving docetaxel: a case series

Cited by 10 publications

References 13 publications

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Periorbital dermatitis in patients receiving docetaxel in combination chemotherapy

Risk of Ocular Adverse Events With Taxane-Based Chemotherapy

Contact Info

Product

Resources

About